There is a new hope for malarial cases in Africa where babies have the highest risk of life due to this dreaded disease. A vaccine which appears to be able to prevent the disease in about 50 percent of children is presently in the final stage of testing.

If the vaccine is determined to be safe by the regulators then it could be on the market in three to five years- the first vaccine against a human parasite.

Millions of Africans are infected by Malaria every year and in the rural Kenyan region next to Lake Victoria, more than one third of the total beds have been dedicated to its victims.

Over a million children die of the disease in Africa annually which has an economy on the verge of crumbling leading to prolonged cycle of the disease and poverty throughout the continent.

Malaria is also common in several regions in Asia, the Middle East and Central and South America.

The vaccine was especially developed for Africa and will only prevent the African strain of the disease.

As per experts this will be a historic breakthrough.

Dr. Dave Jones, a U. S. Army colonel and director of a clinic in nearby Kombewa operated by the Walter Reed Army Institute of Research and the Kenya Medical Research Institute said, "some may say, '50 percent, that's not great.' And that's true. If you get measles vaccine, you're not going to get measles again."

The vaccine has been under the process of development for more than the last 20 years through the combined efforts of GlaxoSmithKline, the Malaria Vaccine Initiative, the Walter Reed Army Institute of Research and others.